T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT

Blood

Volumn 124, Issue 17, 2014, Pages 2735-2743

  Luo, Yi ^a   Xiao, Haowen ^a,b   Lai, Xiaoyu ^a   Shi, Jimin ^a   Tan, Yamin ^a   He, Jingsong ^a   Xie, Wanzhuo ^a   Zheng, Weiyan ^a   Zhu, Yuanyuan ^a   Ye, Xiujin ^a   Yu, Xiaohong ^a   Cai, Zhen ^a   Lin, Maofang ^a   Huang, He ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Guangzhou Liuhuaqiao Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; LYMPHOCYTE ANTIBODY; METHOTREXATE; METHYL N (2 CHLOROETHYL) N CYCLOHEXYL N NITROSOUREA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITROSOUREA DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLELE; ARTICLE; BRONCHIOLITIS OBLITERANS; CAUSE OF DEATH; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAUGHTER; DISEASE FREE SURVIVAL; DONOR; FATHER; FEMALE; FOLLOW UP; GENE LOCUS; GRAFT FAILURE; GRAFT VERSUS LEUKEMIA EFFECT; HAPLOIDY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HLA SYSTEM; HUMAN; IMMUNOTHERAPY; INCIDENCE; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MATCHED SIBLING DONOR; MORTALITY; MOTHER; MYELOABLATIVE CONDITIONING; PROPHYLAXIS; RECURRENCE RISK; RELAPSE; SON; T CELL REPLETE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION; T LYMPHOCYTE; UNRELATED DONORS; ALLOTRANSPLANTATION; BLOOD DONOR; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDY; SIBLING; TREATMENT OUTCOME; TUMOR RECURRENCE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTILYMPHOCYTE SERUM; BLOOD DONORS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; SIBLINGS; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UNRELATED DONORS; YOUNG ADULT;

EID: 84908227872     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-04-571570     Document Type: Article

References (43)

1. Koh LP, Chao N. Haploidentical hematopoietic cell transplantation. Bone Marrow Transplant. 2008;42(suppl 1):S60-S63.
2. Ballen KK, King RJ, Chitphakdithai P, et al. The national marrow donor program 20 years of unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008;14(9, suppl):2-7.
3. Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med. 2001;344(24):1815-1822.
4. Long GD, Laughlin M, Madan B, et al. Unrelated umbilical cord blood transplantation in adult patients. Biol Blood Marrow Transplant. 2003;9(12):772-780.
5. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339(17):1186-1193.
6. Aversa F, Terenzi A, Carotti A, et al. Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia. J Clin Oncol. 1999;17(5):1545-1550.
7. Huang XJ, Liu DH, Liu KY, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies [published correction appears in Bone Marrow Transplant. 2008;42(4):295]. Bone Marrow Transplant. 2006;38(4):291-297.
8. Schlenk RF, Döhner K, Mack S, et al. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol. 2010;28(30):4642-4648.
9. Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487-494.
10. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia (version 2.2013). http://www.nccn.org.
11. Bachanova V, Weisdorf D. Unrelated donor allogeneic transplantation for adult acute lymphoblastic leukemia: a review. Bone Marrow Transplant. 2008;41(5):455-464.
12. Cao W, Xiao H, Lai X, et al. Genetic variations in the mycophenolate mofetil target enzyme are associated with acute GVHD risk after related and unrelated hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18(2):273-279.
13. Xiao H, Luo Y, Lai X, et al. Genetic variations in T-cell activation and effector pathways modulate alloimmune responses after allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies. Haematologica. 2012;97(12):1804-1812.
14. Zhu X, Lai X, Luo Y, et al. Combination of low-dose mycophenolate mofetil with cyclosporine and methotrexate as GVHD prophylaxis in unrelated donor allogeneic stem cell transplantation. Leuk Res. 2013;37(9):1046-1051.
15. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-828.
16. Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant. 2007;40(4):381-387.
17. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706.
18. Kiehl MG, Kraut L, Schwerdtfeger R, et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol. 2004;22(14):2816-2825.
19. Yakoub-Agha I, Mesnil F, Kuentz M, et al; French Society of Bone Marrow Transplantation and Cell Therapy. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol. 2006;24(36):5695-5702.
20. Schetelig J, Bornhäuser M, Schmid C, et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol. 2008;26(32):5183-5191.
21. Gupta V, Tallman MS, He W, et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood. 2010;116(11):1839-1848.
22. Ringdén O, Pavletic SZ, Anasetti C, et al. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood. 2009;113(13):3110-3118.
23. Aversa F, Berneman ZN, Locatelli F, et al. Fourth International Workshop on Haploidentical Transplants, Naples, Italy, July 8-10, 2004. Blood Cells Mol Dis. 2004;33(3):159-175.
24. Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood. 1994;84(11):3948-3955.
25. Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23(15):3447-3454.
26. Aversa F. Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States. Bone Marrow Transplant. 2008;41(5):473-481.
27. Kanda J, Chao NJ, Rizzieri DA. Haploidentical transplantation for leukemia. Curr Oncol Rep. 2010;12(5):292-301.
28. Handgretinger R, Klingebiel T, Lang P, et al. Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant. 2001;27(8):777-783.
29. Burroughs LM, O'Donnell PV, Sandmaier BM, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14(11):1279-1287.
30. Kasamon YL, Luznik L, Leffell MS, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010;16(4):482-489.
31. Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641-650.
32. Solomon SR, Sizemore CA, Sanacore M, et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant. 2012;18(12):1859-1866.
33. Raiola AM, Dominietto A, Ghiso A, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant. 2013;19(1):117-122.
34. Bashey A, Zhang X, Sizemore CA, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol. 2013;31(10):1310-1316.
35. Wang Y, Liu DH, Liu KY, et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer. 2013;119(5):978-985.
36. Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98(10):2942-2947.
37. Finke J, Schmoor C, Lang H, Potthoff K, Bertz H. Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin. J Clin Oncol. 2003;21(3):506-513.
38. Bacigalupo A, Lamparelli T, Barisione G, et al; Gruppo Italiano Trapianti Midollo Osseo (GITMO). Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant. 2006;12(5):560-565.
39. Finke J, Bethge WA, Schmoor C, et al; ATG-Fresenius Trial Group. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855-864.
40. Huang XJ, Liu DH, Liu KY, et al. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant. 2009;15(2):257-265.
41. Wang Y, Chang YJ, Xu LP, et al. Who is the best donor for a related HLA haplotype-mismatched transplant? Blood. 2014;124(6):843-850.
42. Ciceri F, Labopin M, Aversa F, et al; Acute Leukemia Working Party (ALWP) of European Blood and Marrow Transplant (EBMT) Group. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood. 2008;112(9):3574-3581.
43. Wang Y, Liu DH, Xu LP, et al. Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison. Biol Blood Marrow Transplant. 2011;17(6):821-830.